Klivira
Request demo

Navigating Cigna Imfinzi Prior Authorization for Oncology Treatments

Efficiently managing **Cigna Imfinzi prior authorization** is crucial for timely patient access to this critical immunotherapy. Klivira integrates directly with Cigna Healthcare's systems to streamline the process.

For revenue cycle leaders and prior authorization teams, the complexities of specialty drug approvals, particularly for high-volume agents like Imfinzi (durvalumab), can lead to significant administrative burden and treatment delays. Understanding Cigna Healthcare's specific requirements and submission pathways is essential to maintaining operational efficiency and ensuring continuity of care.

Understanding Cigna Imfinzi Prior Authorization Requirements

Imfinzi (durvalumab) is an immunotherapy often requiring prior authorization across commercial and Medicare Advantage plans. Cigna Healthcare manages these approvals through distinct channels depending on the benefit (medical or pharmacy) and site of administration. Klivira streamlines the submission process by aligning with Cigna's specific criteria and pathways.

Key Submission Channels for Imfinzi with Cigna Healthcare

  • **Medical Benefit:** Submissions for physician-administered Imfinzi route via CignaforHCP.com, Cigna Healthcare's provider portal, or X12 278 transactions through clearinghouses.
  • **Pharmacy Benefit:** For pharmacy-dispensed Imfinzi, prior authorizations are managed by Express Scripts, operating under the Evernorth health services brand.
  • **Specialty Pharmacy:** Accredo, Evernorth's specialty pharmacy, handles PAs for specialty injectables and complex medications like Imfinzi when dispensed through the pharmacy benefit.
  • **ePA Platforms:** Express Scripts leverages established electronic PA capabilities through partners like CoverMyMeds and Surescripts for prescriber-initiated workflows.

Navigating Cigna's Medical Necessity Criteria for Imfinzi

Cigna Healthcare publishes specific coverage policies and medical-necessity guidelines on its public provider site, often referencing NCCN Compendium for oncology drugs. These policies detail clinical indications, required preceding therapies, and documentation standards for Imfinzi approval. Klivira helps ensure all necessary clinical documentation is attached and aligned with the current policy version.

Prior Authorization Turnaround Times and Compliance

Cigna Healthcare's PA turnaround times are influenced by state insurance regulations for commercial plans and by CMS-0057-F for Medicare Advantage plans, mandating 72-hour standard and 24-hour expedited review periods. Klivira's automation helps track these timelines, ensuring submissions are processed within regulatory windows.

Electronic Prior Authorization and Da Vinci Initiatives

Cigna Healthcare participates in the HL7 Da Vinci Project ecosystem, indicating a strategic direction towards advanced electronic prior authorization (ePA) capabilities. Express Scripts already maintains robust ePA integrations with platforms like CoverMyMeds and Surescripts for pharmacy benefit drugs, facilitating faster digital submissions for Imfinzi.

Common Denial Reasons and Appeals for Imfinzi

  • **Medical Necessity:** Insufficient documentation of clinical criteria or failure to meet Cigna Healthcare's specific policy guidelines.
  • **Step Therapy:** Lack of documented adherence to required preceding therapies or formulary sequencing.
  • **Site-of-Service Mismatch:** Discrepancies between the proposed site of care and Cigna Healthcare's site-of-service policies.
  • **Non-Formulary Pharmacy:** Denials related to Imfinzi not being dispensed through Express Scripts or Accredo when required.
  • **Appeal Process:** Cigna Healthcare outlines appeal pathways on CignaforHCP.com, including peer-to-peer reviews for clinical denials, with distinct processes for commercial and Medicare Advantage lines.

Frequently asked questions

What are the primary submission channels for Cigna Imfinzi prior authorization?

For medical benefit Imfinzi, submit via CignaforHCP.com or X12 278. For pharmacy benefit, Express Scripts (under Evernorth) manages PAs, often leveraging ePA platforms like CoverMyMeds and Surescripts. Accredo, their specialty pharmacy, handles specific specialty injectable PAs.

Which entity manages the pharmacy benefit for Imfinzi under Cigna Healthcare?

Express Scripts, operating under the Evernorth health services brand, manages the pharmacy benefit for Cigna Healthcare. This includes prior authorizations for pharmacy-dispensed specialty drugs like Imfinzi. Accredo, an Evernorth specialty pharmacy, often handles the dispensing and associated PAs.

Where can I access Cigna Healthcare's medical necessity criteria for Imfinzi?

Cigna Healthcare publishes its coverage policies and medical-necessity guidelines on its public provider website. These policies are versioned and dated, often citing NCCN Compendium for oncology drugs like Imfinzi, and detail the clinical requirements for approval.

What are common reasons for Cigna Healthcare to deny prior authorization for Imfinzi?

Frequent denial reasons include insufficient documentation of medical necessity, failure to meet step therapy requirements, or discrepancies with site-of-service policies. Denials for pharmacy-dispensed Imfinzi may also relate to not using the formulary-preferred specialty pharmacy, Accredo.

How does Klivira integrate with Cigna Healthcare's PA process for Imfinzi?

Klivira automates the submission of Imfinzi prior authorizations by integrating with CignaforHCP.com and leveraging X12 278 transactions. For pharmacy benefit drugs, Klivira connects with Express Scripts' ePA partners, streamlining document submission, status tracking, and denial management across Cigna Healthcare's diverse channels.

Related coverage

Other imfinzi prior authorization by payer

Other imfinzi prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo